

Access the entire webinar series here:

<https://files.asprtracie.hhs.gov/documents/aspr-tracie-healthcare-operations-during-covid-19-pandemic-webinar-series.pdf>

Access this webinar recording here: [https://](https://attendee.gotowebinar.com/recording/8534472339464849168)

attendee.gotowebinar.com/recording/8534472339464849168



TRACIE

HEALTHCARE EMERGENCY PREPAREDNESS
INFORMATION GATEWAY

Healthcare Operations during the COVID-19 Pandemic- Speaker Series

January 2021

Unclassified//For Public Use



Access Dr. Fales's bio here: <https://med.wmich.edu/node/996>



TRACIE

HEALTHCARE EMERGENCY PREPAREDNESS
INFORMATION GATEWAY

William Fales, MD, FACEP, FAEMS

Medical Director, Michigan Department of Health & Human Services, Division of EMS and Trauma; Professor and Chief, Division of EMS and Disaster Medicine, Western Michigan University

Unclassified//For Public Use



Disclosures and Conflicts

- **Disclosures**

- Western Michigan University Homer Stryker MD School of Medicine
 - Professor of Emergency Medicine
 - Chief, Division of EMS and Disaster Medicine
- Kalamazoo County Medical Control Authority
 - EMS Medical Director

- **Conflicts**


- No known conflicts

Methods for Monoclonal Antibody (mAb) Therapy

- mAb authorized by FDA and allocated by HHS to the states (and others)
- mAb therapy is allocated from the states to healthcare facilities
- Michigan initially supplied exclusively hospitals as community “depot”
 - Supply intended for hospital use but also for broad community
 - Since, expanded direct allocation to others (LTC pharmacies, infusion clinics)
- State’s concerns: **Equity, Safety, and Efficacy**
- Electronic Patient Profile Form submitted for each patient treated
- Electronic Follow-up Form for admissions/deaths within 14 days of mAb
- Follow-up brief phone interviews to evaluate post-mAb course




mAb in Michigan – Supply >>> Demand




*Partial week **Source: HHS/ASPR www.phe.gov

Hospital Use (or Lack Th

- Use reported by 50 of 138 (36%) hospitals
- 221 (15%) patients at one hospital
- 10 hospitals treated ~60% of patients
 - 12 hospitals treated 1% of patients
- Detroit (91) vs. Upper Peninsula (157)
- Smaller vs. larger hospitals
 - Level 1/2 trauma centers: 20
 - Non-level 1/2 trauma centers: 30
- Medication used
 - Bamlanivimab: 97%
 - Casirivimab/Imdevimab: 3%




mAb Therapy by Administering Hospital or Health Care Facility - N=1,501



mAb and Michigan Hospitals

Top 10 Hospitals




ASPR
ASSISTANT SECRETARY FOR
PREPAREDNESS AND RESPONSE


TRACIE
HEALTHCARE EMERGENCY PREPAREDNESS
INFORMATION GATEWAY

Demographics

mAb by Age Group - N=1,501




mAb by Race - N=1,501





- 50.6% Female
- 10.0% Healthcare Workers


Risk Factors for Disease Progression & Signs and Symptoms



mAb Infusion Location and post-mAb Destination



Safety: mAb Infusion Related Problems



Efficacy: Post mAb Admission Rate and Outcome

Total	Age >64 YO	Age 55-64 w/RF	BMI >34	CKD	DM	Immuno-Suppress Disease	Immuno-Suppress Treatment
772	457	110	231	42	136	31	33
39	22	2	15	3	8	0	3
5.1%	4.8%	1.8%	3.6%	7.7%	5.9%	0.0%	10.0%

Reported Hospitalization Rates in Untreated High-Risk Patients from Clinical Trials
9 to 15%

Phone Interviews N=152

- Admit: 5.9%
- 2-Day Improved: 66.4%
- Now improved: 96.6%

Operation Holiday Delivery

- Rapid Response to LTCs with 6 outbreaks
 - 6 counties, 5 SNFs, 1 Assisted Living
- Resources: State Mobile Nursing Crisis Teams + Local EMS/Paramedics
- Outcomes: 101 patients, 3 admits, 1 death



Access to LTC Patients

Awareness

- Facility Medical Director/Clinicians
- Local Public Health
- Healthcare Coalitions



Delivery Options

- Transport to infusion center or ED
- SNFs - Internal Staff
- Home care/infusion
- EMS (per protocol)
- Special Team

- mAb therapy is underutilized in Michigan
- mAb supply far exceeds current demand
- Bamlanivimab has been found to be safe
- Treatment in LTC settings of large numbers of patients can be safe and efficient using multi-disciplinary teams
- Ability of mAb to reduce hospitalizations remains to be determined but preliminary experience is encouraging

Contact Us



asprtracie.hhs.gov



1-844-5-TRACIE



askasprtracie@hhs.gov

falesw@michigan.gov